New drug combo aims to tailor myeloma treatment to each patient

NCT ID NCT07624513

Not yet recruiting Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consolidation and maintenance therapy—will be chosen based on each patient's risk profile and how well their cancer responds. The goal is to find the best treatment path for each individual, aiming for deeper and longer-lasting remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab, iberdomide, bortezomib, and dexamethasone
What this could lead to: If successful, this could lead to a more personalized treatment plan for multiple myeloma, potentially improving long-term disease control and reducing the chance of relapse.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The combination of drugs may cause significant side effects, and the risk-adapted approach may not benefit all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center (BIDMC)

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.